Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Feb;28(2):283-6.
doi: 10.1007/s00381-011-1576-9. Epub 2011 Sep 18.

Osteopenia in children with cerebral palsy can be treated with oral alendronate

Muhammet Sukru Paksu  1 , Sebahattin Vurucu, Abdulbaki Karaoglu, Alper Ozgur Karacalioglu, Ahmet Polat, Ozgur Yesilyurt, Bulent Unay, Ridvan Akin
Affiliations
Clinical Trial

Osteopenia in children with cerebral palsy can be treated with oral alendronate

Muhammet Sukru Paksu et al. Childs Nerv Syst. 2012 Feb.

Erratum in

Abstract

Purpose: Cerebral palsy is one of the most common reasons of osteopenia in childhood. Patients have a significantly decreased bone mineral density, and painful fractures with minor traumas are common. Biphosphonates in the treatment of childhood osteoporosis are increasingly being used. This study aimed to evaluate the efficacy of oral alendronate treatment in children with cerebral palsy.

Methods: Twenty-six children (16 boys and 10 girls) aged 3 to 17 years who had quadriplegic cerebral palsy and osteopenia were included in the study. The patients received alendronate (1 mg/kg/week), calcium (600 mg/day), and vitamin D(3) (400 U/day) over a year. A complete blood count, kidney and liver functional tests, plasma calcium, phosphate and alkaline phosphatase levels, and lumbar vertebral bone mineral density were measured before and after treatment.

Results: Compared with pretreatment values, bone mineral density, serum calcium, and phosphate levels of the patients statistically increased and alkaline phosphatase levels decreased after treatment. No patient needed to interrupt treatment because of side effects.

Conclusions: Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective.

PubMed Disclaimer

References

    1. Pediatr Int. 2001 Apr;43(2):157-60 - PubMed
    1. Cochrane Database Syst Rev. 2008 Oct 08;(4):CD005088 - PubMed
    1. Acta Orthop Belg. 2005 Feb;71(1):91-7 - PubMed
    1. Paediatr Drugs. 2005;7(5):295-323 - PubMed
    1. J Pediatr. 2005 Jun;146(6):769-75 - PubMed

Publication types